European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

The European Commission has approved Vabysmo for treating vision impairment due to macular edema caused by retinal vein occlusion (RVO). Data from two Phase III studies showed Vabysmo's effectiveness in improving vision in people with both branch and central RVO. In the studies, Vabysmo achieved similar vision gains to aflibercept and provided robust retinal drying, reducing excess fluid in the eye. Vabysmo is the first bispecific antibody targeting both Ang-2 and VEGF-A for eye diseases. It stabilizes blood vessels by blocking these pathways, contributing to vision loss. Up to 60% of patients treated with Vabysmo were able to extend treatment intervals to three or four months, providing convenience. Vabysmo is already approved in numerous countries, including the US and Japan, for treating RVO, nAMD, and DME. Together, these conditions affect nearly 80 million people worldwide and are major causes of vision loss. The safety profile of Vabysmo has been consistent with previous studies, making it a well-tolerated treatment option. Vabysmo's approval expands treatment options for people with RVO in Europe, offering them hope for preserving and improving their vision.